Objective To investigate the clinical effect of amlodipine combined with Telmisartan Capsules in the treatment of hypertension.MethodsThe patients with primary hypertension in 87 cases in the second hospital affiliated to Tianjin Medical University were divided into two groups.43 patients in control group were treated with amlodipine 2.5~5mg/d orally, 44 patients in the experimental group on the basis of combined with Telmisartan Capsules 40~80mg/d orally, the total course of treatment was eight weeks.The changes of blood pressure levels were compared before and after treatment, the effective rate of the treatment and adverse reactions after treatment, to evaluate the clinical efficacy of amlodipine combined with Telmisartan Capsules in the treatment of hypertension.ResultsAfter treatment, two groups of three blood pressure index were significantly decreased (P<0.05), compared with the control group, the experimental group of patients with treatment After treatment the blood pressure level is low(P<0.05).After eight weeks of treatment, the total efficiency of control group was 72.09%, the total efficiency of experimental group was 95.45%, the experimental group was higher than that in the control group (P<0.05) after treatment, patients in the control group with two cases of headache (4.65%), two cases of lower extremity edema (4.65%);the experimental group of two cases of vertigo (4.55%), three cases of joint pain (6.82%), there was no significant difference in total adverse reaction rate between the two groups.Conclusion Amlodipine combined with Telmisartan Capsules in the treatment of hypertension has good clinical effect.

Objective To investigate the clinical value and safety of cedilanid, esmolol in the treatment of atrial fibrillation. Methods From August 2014 to August 2016 our Hospital from 117 patients with atrial fibrillation clinical data, according to the random number distribution principle, the patients were divided into observation group 59 cases and control group of 58 cases, all patients were given the treatment of primary disease, the clinical symptoms, the patients in the observation group were given oxygen, has given furosemide, cedilanid, after micro injection pump intravenous nitroglycerin, 5-20 g/min. Start after the injection of nitroglycerin, establish another vein channel, every 30 min to 0.2 mg patients, the treatment group were treated with intravenous injection of small dose esmolol. The clinical efficacy, ventricular rate, systolic blood pressure, diastolic blood pressure and adverse reactions were observed in two groups. Results The early and late effective rates of the two groups were not significantly different. The observation showed that after treatment, the ventricular rate, systolic pressure and diastolic pressure in the observation group were significantly higher than those in the control group (P<0.05), and the incidence of adverse reactions in the two groups was significantly different (P<0.05). Conclusion High dose cedilanid combined with small dose esmolol in treatment of atrial fibrillation, obvious curative effect, high safety, can choose the appropriate application.

Myeloid neoplasms (MNs) belong to a group of hematological malignancies characterized by the abnormal biological functions of hematopoietic stem progenitor cells. The abnormal immune and hematopoietic microenvironment of patients with MN interact with malignant clonal hematopoietic stem cells, promoting the occurrence and development of their diseases. MN large granular lymphocyte proliferation (MN-LGLP) is a special and rare clinical phenomenon in this type of disease. Currently, research on this disease in domestic and international cohorts is limited. This study analyzes the clinical and laboratory characteristics of this type of patient and explores the impact of LGLP on the clinical characteristics and survival of patients with MN. Patients with MN-LGLP are prone to neutropenia and splenomegaly. The presence of LGLP is not a risk factor affecting the survival of patients with MN-LGLP. STAG, ASXL1, and TET2 are the most common accompanying gene mutations in MN-LGLP, and patients with MN-LGLP and STAG2 mutations have poor prognoses.